Nasopharyngeal carcinoma (NPC), a malignancy that develops in the upper section of the throat behind the nose, occurs in ...

More information: Eugenia Li Ling Yeo et al, Tumor immune microenvironment delineates progression trajectories of distinct nasopharyngeal carcinoma phenotypes, Cell Reports Medicine (2025).

BeOne Medicines has secured approval from the European Commission (EC) for Tevimbra (tislelizumab) to be used along with ...

(NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Commission has approved TEVIMBRA ® (tislelizumab), in combination with gemcitabine and cisplatin, ...

A novel immuno-PET/CT imaging technique has identified and validated a potent biomarker for nasopharyngeal cancer (NPC). The biomarker, CD70, is highly and constantly expressed in NPCs, and CD70 ...

In a significant step toward improving targeted cancer therapy, researchers from Japan have developed a novel nanocarrier ...

The fluorescent labeling compound—dubbed "Sialyl Lewis Yellow"—was developed by an international team led from the Pohang University of Science and Technology in South Korea. It works by binding to ...

During a median follow-up period of 17.8 years, higher incidence rates for all cancers were generally associated with higher baseline hs-cTnT and NT-proBNP levels, especially for the highest quartiles ...

BAMF Health in Grand Rapids has launched a study to identify markers for targeted breast cancer therapies using PET scans.

The test detected two common cancer markers—carcinoembryonic antigen (CEA) and prostate-specific antigen (PSA)—at levels ten times lower than standard ELISA kits.